manag
nasal
allergi
pharmacotherapi
major
part
practic
otolaryngologist
allergist
well
primari
care
physician
use
topic
prepar
purpos
becom
increasingli
popular
new
better
drug
sever
type
continu
topic
cromolyn
use
treatment
mild
moder
allerg
rhiniti
exert
protect
therapeut
effect
stabil
mast
cell
degranul
corticosteroid
potent
antiinflammatori
action
frequent
use
treat
moder
sever
rhiniti
topic
corticosteroid
use
continu
increas
follow
introduct
beclomethason
new
prepar
becom
avail
increas
frequenc
cromolyn
mastcel
stabil
introduc
develop
nedocromil
nedocromil
potent
cromolyn
combin
mastcel
stabil
properti
broad
antiinflammatori
action
affect
inflammatori
respons
sever
site
like
cromolyn
nedocromil
inhibit
immedi
late
phase
allerg
reaction
nedocromil
sodium
disodium
salt
pyranoquinolin
dicarboxyl
acid
stabil
mucos
connect
tissu
mast
cell
well
eosinophil
monocyt
epi
thelial
cell
alveolar
macrophag
mucos
mastcel
stabil
potenc
nedocromil
determin
least
time
cromolyn
sodium
also
biopsi
studi
nasal
mucou
membran
shown
treatment
nedocromil
sodium
significantli
inhibit
accumul
mast
cell
within
addit
nedocromil
appear
suppress
action
format
multipl
mediat
includ
histamin
leukotrien
c
prostaglandin
although
statist
comparison
difficult
appear
clinic
assess
nedocromil
significantli
potent
treatment
allerg
rhiniti
nedocromil
administ
topic
nose
solut
dispens
pump
spray
case
cromolyn
pretreat
nasal
mucosa
topic
nedocromil
allergen
challeng
significantli
reduc
effect
nasal
obstruct
rhinorrhea
sneez
addit
protect
effect
intranas
nedocromil
administ
time
daili
ragweedallerg
patient
ragwe
season
shown
significantli
reduc
sneez
rhinorrhea
itch
membran
nasal
congest
sleep
disturb
due
allerg
symptom
requir
concomit
medic
similar
benefici
effect
demonstr
doubleblind
placebocontrol
studi
nedocromil
administ
patient
grass
allergi
peak
pollen
nedocromil
combin
astemizol
demonstr
much
effect
antihistamin
alon
reliev
allerg
rhiniti
symptomsl
effect
intranas
nedocromil
must
wide
dispers
involv
areal
may
requir
initi
concomit
administr
decongest
use
salin
nasal
spray
flush
thick
secret
nose
nedocromil
spray
administ
nedocromil
like
cromolyn
ineffect
treatment
applic
anticip
acut
allergen
exposur
nedocromil
use
asneed
basi
rather
adequ
control
symptom
mild
moder
allerg
rhiniti
nedocromil
must
use
regularli
throughout
patient
usual
allerg
season
howev
clinic
experi
indic
effect
symptom
control
achiev
time
daili
dosag
mainten
dose
may
decreas
frequenc
time
daili
nedocromil
except
safeti
profil
low
incid
report
side
effect
gener
mild
consist
primarili
nasal
dryness
sting
proport
less
observ
patient
receiv
constitut
symptom
attribut
topic
administ
nedocromil
report
refer
review
munolog
challeng
sulfur
dioxid
placebocontrol
studi
administr
intranas
nedocromil
volunt
infect
rhinoviru
significantli
lower
daili
symptom
score
daili
mean
nasal
group
infect
coronaviru
statist
signific
differ
two
group
demonstr
although
clinic
indic
favor
nedocromil
group
group
rhinoviru
coronaviru
nedocromil
administr
improv
symptom
infect
individu
author
conclud
one
mediat
affect
nedocromil
involv
product
symptom
viral
respiratori
infect
form
nedocromil
current
avail
unit
state
pulmonari
administr
inhal
aerosol
deliv
via
meter
dose
inhal
tilad
fison
corpor
rochest
ny
studi
shown
safe
effect
firstlin
agent
prevent
manag
asthma
whether
allerg
nonallerg
gener
nedocromil
believ
potent
safe
firstlin
mainten
therapi
mild
moder
asthma
adult
cromolyn
proven
pediatr
nasal
solut
initi
dose
frequenc
time
daili
howev
gener
possibl
maintain
adequ
asthma
control
twicedaili
regimen
although
approv
use
mani
physician
found
clinic
experi
topic
applic
cromolyn
effect
protect
mani
patient
nasal
symptom
produc
nonimmunolog
trigger
eg
irrit
fume
insuffici
experi
gather
nedocromil
judg
whether
also
effect
situat
howev
uniqu
dual
action
mastcel
stabil
antiinflammatori
action
make
like
use
would
appropri
inhal
challeng
studi
asthma
nedocromil
consist
potent
cromolyn
sodium
nonimnedocromil
sodium
mastcel
stabil
prevent
ablat
acut
late
phase
allerg
respons
antiinflammatori
agent
steroid
potent
current
avail
mastcel
stabil
cromolyn
mainten
therapi
may
possibl
less
frequent
interv
initi
recommend
regimen
time
daili
nedocromil
pulmonari
administr
current
avail
nasal
form
undergon
clinic
trial
yet
releas
unit
state
